Keyword: Sandoz

AbbVie has inked a fourth patent deal on its megablockbuster Humira that forces Novartis to the back of the line for a U.S. launch.

Novartis' Sandoz is stirring things up in the epinephrine market—and it's about to stir things up in the pediatric epinephrine market, too.

Novartis’ traditional pill manufacturing will shoulder the brunt of a cost-cutting effort announced Tuesday as it looks to a future in biologic drugs.

At least three new emergency epinephrine marketers are challenging longtime market leader Mylan and its EpiPen.

Can Humira really avoid the biosimilar bloodletting that's hit Merck's Remicade and Pfizer's Enbrel in the EU? Execs say yes. Analysts now aren't so sure.

Investors might see the deal as "a proxy for what the commodity portions of Teva’s U.S. and Mylan’s U.S. businesses might be worth," says an analyst.

Aurobindo buys parts of Sandoz for $1B; an ex-GSK scientist admits to stealing trade secrets; Lilly and Chi-Med's Chinese-made drug makes history.

The deal relieves Novartis of a troubled franchise while boosting buyer Aurobindo to the second-largest generics player by prescriptions in the U.S.

CDMO Olon is continuing its expansion binge with a deal to buy an API plant in India that supplies ingredients to Novartis.

A Nebraska lawmaker wrote to Pfizer in an attempt to spur the drugmaker to sue against the use of its drugs in a lethal injection.